First Quarter 2018 Investor Presentation

Investor Presentation First three months of 2018 Slide 51 Solid insulin market leadership position in Region Japan & Korea Japan & Korea insulin market by segment Japan & Korea modern and new-generation insulin volume market shares Device penetration - tMU MI and NGI penetration CAGR volume¹: 0.5% Penetration Novo Nordisk - Sanofi Eli Lilly 6 4 2 16 14 12 CAGR value¹: (4.4%) 100% 70% 60% 80% Fast-acting 50% 50% 10 8 6 4 2 0 Feb 2013 60% 40% Premix 30% 40% 20% 25% 25% Long-acting 20% 10% 0% 0% Feb 2018 Feb 2013 Feb 2018 1 CAGR for 5-year period MI: Modern insulin; NGI: New-generation insulin Source: IQVIA monthly MAT Feb, 2018 volume and value (DKK) figures changing diabetes® Source: IQVIA monthly MAT Feb, 2018 volume figures novo nordisk

View entire presentation